Clinical Trial Update: CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

View source ↗

Summary

The CD INFORM observational study of natalizumab for Crohn's disease has been terminated, ending further observational research and monitoring.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Crohn's Disease | Status: TERMINATED